TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05625360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Mindful Movement and Breathing
Description: The self-directed intervention includes an approximately 20-minute eMMB will teach synergistic components: (a) Mindful Meditation - 2 minutes of observing the current state of the body, emotions, thoughts, energy, and breath. Mindful attention may facilitate safe physical movements; (b) Mindful Movement - 10 minutes of gentle movements coordinated with and intended to enhance the breath; (c) Breathing and Relaxation - 3 minutes of placing the hands above the navel (rather than on the belly to avoid discomfort) and noticing them rise and fall with a focus on slightly extending the exhale, which will prepare participants for meditation); (d) Meditation - 5 minutes of observing the natural breath without reacting to it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life Impacts Reflection
Description: This self-directed intervention will focus on active listening, reflection of statements, and avoiding negative judgments. Participants will write brief diary entries daily for four weeks postoperatively and as they choose thereafter. Participants will be given the option of completing diaries on the tablet computer or paper. The instructions for daily diary entries will be, What were some of the events or circumstances that affected you in the past day? Think back over the past day and write down on the lines below up to five events that had an impact on you. A study team member will call participants to encourage diary completion two days (Postop Day 3) and two weeks after the synchronous session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS Questionnaires
Description: Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS Questionnaires
Description: Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
Study: NCT05213975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio taping
Study: NCT04848675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training
Description: Participants will perform inspiratory muscle strength training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brisk walking
Description: Participants will perform brisk walking.
Study: NCT06077656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25 Formulation A
Description: 25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25 Formulation B
Description: 25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25 Formulation C
Description: 25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 20
Description: 20 valent pneumococcal conjugate vaccine
Study: NCT05782868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing in response to vignette
Description: Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing in response to vignette
Description: Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing about events of the day
Description: Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter of Gratitude
Description: Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
Study: NCT05295849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Habits Together Online Weight Loss 6-Week Usability Trial
Description: The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
Study: NCT06195709

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Endocrine therapy
Description: Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Endocrine therapy combined with the local treatment of FES-negative lesions
Description: Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
Study: NCT05397327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D virtual planning software
Description: 3D virtual planning software developed by Sectra AB (Linköping, Sweden)
Study: NCT03101917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Microtable® Stereotactic System
Description: x

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Microtable® Stereotactic System
Description: x
Study: NCT04803383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Tele-yoga training 3 days a week for 8 weeks
Study: NCT05738174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-dose accelerated intermittent theta burst stimulation
Description: 1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high-dose accelerated intermittent theta burst stimulation
Description: 1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
Study: NCT06234059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking Tasks
Description: Participants will produce four training words under a vowel centralization feedback paradigm in which auditory feedback is altered. The investigators will measure changes in produced vowels as a result of the altered feedback in concert with the different stimulation regimes described in the TMS intervention.
Study: NCT05747443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Reminders
Description: Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Reminders
Description: Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: The Patient Voices Video is an educational video about lung cancer screening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: The Patient Voices Video is an educational video about lung cancer screening.
Study: NCT05473026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Intervention
Description: Gratitude journaling and goal setting for exercise readiness over eight weeks.
Study: NCT06589466

Intervention type: OTHER
Intervention: Surgery
Description: this study in observational study, no intervention.
Study: NCT06593483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview with Self-Talk Video
Description: Participants will engage in an interview based in motivational interviewing techniques and then record a self talk video discussing their goals and reasons for reducing their drinking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Participants will engage in an interview based in motivational interviewing
Study: NCT06068868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-787
Description: Intravenous (IV) Infusion
Study: NCT05019690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
Study: NCT05206734

Intervention type: OTHER
Intervention: Exposure of mental health condition
Description: Primary:~Composite of all chronic psychological conditions (depression, anxiety, eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorder, acute stress disorder, and post-traumatic stress disorder).~Major recurrent depression or treated depressive episode. Non-phobia related anxiety episode or disorder.~Secondary:~Self-harm, suicide attempt or suicide related codes, other chronic psychiatric conditions (eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorders, acute stress disorder, schizophrenia, bipolar disorder and post-traumatic stress disorder. Problems with sleep.

Intervention type: OTHER
Intervention: Exposure of mental health condition
Description: Primary:~Composite of all chronic psychological conditions (depression, anxiety, eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorder, acute stress disorder, and post-traumatic stress disorder).~Major recurrent depression or treated depressive episode. Non-phobia related anxiety episode or disorder.~Secondary:~Self-harm, suicide attempt or suicide related codes, other chronic psychiatric conditions (eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorders, acute stress disorder, schizophrenia, bipolar disorder and post-traumatic stress disorder. Problems with sleep.
Study: NCT06186323

Intervention type: BEHAVIORAL
Intervention: Affordances in the Home Environment for Motor Development-Infant Scale
Description: Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.

Intervention type: BEHAVIORAL
Intervention: Peabody Developmental Motor Scales-2
Description: Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills

Intervention type: BEHAVIORAL
Intervention: Test Of Sensory Functions In Infants (TSFI)
Description: his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
Study: NCT04861597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet based cognitive behavioral therapy
Description: Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital mood tracking
Description: Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
Study: NCT06300580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Oral Capsule
Study: NCT05267262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R3R01
Description: R3R01 administered orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R3R01
Description: R3R01 administered orally for 12 weeks
Study: NCT06092749

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transgrade technique (TG)
Description: Transgrade (TG) Epidural Steroid Injection technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interlaminar technique (IL)
Description: Interlaminar (IL) Epidural Steroid Injection technique
Study: NCT05517135

Intervention type: OTHER
Intervention: Arm 1
Description: Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC). For AC, physicians can choose between cisplatin-5FU d1-4, q4w for 3 cycles, or capecitabine 650 mg/m2 bid for 12 months or 1000 mg/m2 bid oral, d1-21, q3w for 6 months

Intervention type: OTHER
Intervention: Arm 2
Description: IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT +/- metronomic capecitabine (650 mg/m2 bid oral for 12 months)

Intervention type: OTHER
Intervention: Arm 3
Description: IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), followed by either of the following:~1. RIBBON-LA-01 (NCT06093061)~2. CCRT + metronomic capecitabine (650 mg/m2 bid oral for 12 months)

Intervention type: OTHER
Intervention: Group 1
Description: Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine

Intervention type: OTHER
Intervention: Group 2
Description: Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
Study: NCT05753046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early TAP Block
Description: For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Late TAP Block
Description: For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
Study: NCT05635786

Intervention type: DRUG
Intervention: Alteplase (0.9mg/kg)
Description: Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.

Intervention type: DRUG
Intervention: Tenecteplase (0.25mg/kg)
Description: Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.
Study: NCT06533969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation
Description: This will be a one time surgery lasting no more than 2 hours where ESCS electrodes will be connected to an external stimulator approved for human research. Stimulation intensity and parameters will be configured before each session for optimal upper extremity motor function.~The ESCS approach will include surgical implantation of temporarily placed leads in the cervical epidural space and connection cables tunneled percutaneously through the skin for \<30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocorticographic
Description: Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalographic
Description: Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
Study: NCT06164951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib 0.25 mg/kg/day
Description: Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator 0.25 mg/kg/day
Description: Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
Study: NCT05899153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomotum Spark: Robotic ankle resistance
Description: Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomotum Spark: Robotic ankle resistance
Description: Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Biofeedback
Description: Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Biofeedback
Description: Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.
Study: NCT05230940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TURKOVAC
Description: Inactive COVID-19 Vaccine - TURKOVAC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: It has 600 subunit of SARS-CoV-2 virus antigen
Study: NCT04335656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum
Description: Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages